Back to homepage

Tag "JAK2"

Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib

Authors: Novin Nezamololama, BSc, MSc, Keira Fieldhouse, BSc, Kristy Metzger, BSc, Melinda Gooderham, MD, MSc, FRCPC

This review summarizes the clinical data available from various trials and reports on the safety and efficacy of abrocitinib, baricitinib, and upadacitinib, the three oral systemic JAK inhibitors used in the treatment of atopic dermatitis.

More